Silver Book Fact

Goel S, Bajaj N, Agaarwall B, Gupta S, et al. Prevalence and Outcomes of Unoperated Patients with Severe Symptomatic Mitral Regurgitation and Heart Failure. J Am Coll Cardiol. 2014; 63(2). http://www.onlinejacc.org/content/63/2/185

Reference

Title
Prevalence and Outcomes of Unoperated Patients with Severe Symptomatic Mitral Regurgitation and Heart Failure
Publication
J Am Coll Cardiol
Publication Date
2014
Authors
Goel S, Bajaj N, Agaarwall B, Gupta S, et al.
Volume & Issue
Volume 63, Issue 2
URL
Read Full Resource

Categories

  • Cost of Disease

Related Facts

  • 1 and 6-month mortality rates without treatment for sSAS
    Waiting for treatment for severe symptomatic aortic stenosis (sSAS) can be deadly, with 1-month mortality at 3.7% and 6-month mortality at 11.6% (measured from the time intervention was recommended).  
  • Low detection rates for AS
    Prevalence estimates for AS are likely low. A U.K. population screening found previously undetected HVD in 1 in 2 adults ages 65+.  
  • Aortic valve disease costs
    Aortic valve disease (AVD) (symptomatic and asymptomatic) costs the U.S. $10.2 billion in direct costs each year.  
  • Survival rates for patients with sSAS without repair or replacement
     
  • Mean 5-Year Cumulative Total Medical Costs Per Medically Managed (No AVR) Severe AS Patient